{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:40:03Z","timestamp":1789807203537,"version":"4.0.1"},"reference-count":146,"publisher":"Frontiers Media SA","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":21,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transpl Int"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1111\/tri.12642","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T02:18:28Z","timestamp":1437531508000},"page":"135-152","source":"Crossref","is-referenced-by-count":16,"title":["Hepatitis C virus and liver transplantation: where do we stand?"],"prefix":"10.3389","volume":"29","author":[{"given":"Patrizia","family":"Burra","sequence":"first","affiliation":[{"name":"Multivisceral Transplant Unit, Gastroenterology; Department of Surgery, Oncology and Gastroenterology; Padua University Hospital; Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Martin","sequence":"additional","affiliation":[{"name":"Multivisceral Transplant Unit, Gastroenterology; Department of Surgery, Oncology and Gastroenterology; Padua University Hospital; Padua Italy"},{"name":"Centre Hepato-Biliaire Paul Brousse; Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zanetto","sequence":"additional","affiliation":[{"name":"Multivisceral Transplant Unit, Gastroenterology; Department of Surgery, Oncology and Gastroenterology; Padua University Hospital; Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Senzolo","sequence":"additional","affiliation":[{"name":"Multivisceral Transplant Unit, Gastroenterology; Department of Surgery, Oncology and Gastroenterology; Padua University Hospital; Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Russo","sequence":"additional","affiliation":[{"name":"Multivisceral Transplant Unit, Gastroenterology; Department of Surgery, Oncology and Gastroenterology; Padua University Hospital; Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Zanus","sequence":"additional","affiliation":[{"name":"Hepatobiliary Surgery and Liver Transplantation Unit; Department of Surgery, Oncology and Gastroenterology; Padua University Hospital; Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[{"name":"Gastroenterology and Transplant Hepatology; Papa Giovanni XXIII Hospital; Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"key":"10.1111\/tri.12642-BIB0001|tri12642-cit-0001","first-page":"320A","article-title":"Ledipasvir\/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study","volume":"60","author":"Flamm","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0002|tri12642-cit-0002","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/jlts.2002.35781","article-title":"Natural history of recurrent hepatitis C","volume":"8","author":"Berenguer","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0003|tri12642-cit-0003","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/TP.0000000000000413","article-title":"Hepatitis C genotype influences post-liver transplant outcomes","volume":"99","author":"Campos-Varela","year":"2015","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0004|tri12642-cit-0004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/lt.23559","article-title":"Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis","volume":"19","author":"Verna","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0005|tri12642-cit-0005","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/lt.20725","article-title":"Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation","volume":"12","author":"Ercolani","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0006|tri12642-cit-0006","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.lts.2003.09.018","article-title":"Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry","volume":"9","author":"Adam","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0007|tri12642-cit-0007","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.TP.0000164291.35925.7A","article-title":"Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection","volume":"80","author":"Condron","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0008|tri12642-cit-0008","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/lt.21093","article-title":"Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study","volume":"13","author":"Belli","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0009|tri12642-cit-0009","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1053\/j.gastro.2005.11.013","article-title":"HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation","volume":"130","author":"Belli","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0010|tri12642-cit-0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/lt.21566","article-title":"Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis","volume":"15","author":"Briceno","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0011|tri12642-cit-0011","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/TP.0b013e318235a1ab","article-title":"Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation","volume":"92","author":"Subramanian","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0012|tri12642-cit-0012","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1478-3231.2007.01490.x","article-title":"Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation","volume":"27","author":"Botha","year":"2007","journal-title":"Liver Int"},{"key":"10.1111\/tri.12642-BIB0013|tri12642-cit-0013","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/lt.21761","article-title":"Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients","volume":"15","author":"Burra","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0014|tri12642-cit-0014","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s10620-012-2345-7","article-title":"Donor diabetes mellitus is an independent risk factor for graft loss in HCV positive but not HCV negative liver transplant recipients","volume":"58","author":"Wu","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1111\/tri.12642-BIB0015|tri12642-cit-0015","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/TP.0b013e318219eb8f","article-title":"Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study","volume":"91","author":"Ballarin","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0016|tri12642-cit-0016","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.transproceed.2012.05.012","article-title":"Liver transplantation from anti-hepatitis C virus-positive donors: our experience","volume":"44","author":"Alvaro","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12642-BIB0017|tri12642-cit-0017","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s00268-011-1019-5","article-title":"Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database","volume":"35","author":"Burr","year":"2011","journal-title":"World J Surg"},{"key":"10.1111\/tri.12642-BIB0018|tri12642-cit-0018","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12659\/AOT.892530","article-title":"Donor hepatitis C sero-status does not impact survival in liver transplantation","volume":"20","author":"Montenovo","year":"2015","journal-title":"Ann Transplant"},{"key":"10.1111\/tri.12642-BIB0019|tri12642-cit-0019","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1432-2277.2010.01092.x","article-title":"Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis","volume":"23","author":"Northup","year":"2010","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12642-BIB0020|tri12642-cit-0020","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1034\/j.1600-6143.2003.00189.x","article-title":"Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis","volume":"3","author":"Saab","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0021|tri12642-cit-0021","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/lt.23854","article-title":"Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients","volume":"20","author":"O'Leary","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0022|tri12642-cit-0022","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.20995","article-title":"Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation","volume":"13","author":"Terrault","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0023|tri12642-cit-0023","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1053\/jlts.2003.50211","article-title":"Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors","volume":"9","author":"Gaglio","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0024|tri12642-cit-0024","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/hep.20357","article-title":"Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation","volume":"40","author":"Garcia-Retortillo","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0025|tri12642-cit-0025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/lt.20254","article-title":"Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation","volume":"10","author":"Thuluvath","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0026|tri12642-cit-0026","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/jlts.2003.50229","article-title":"Hepatic regeneration in living donor liver transplantation","volume":"9","author":"Olthoff","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0027|tri12642-cit-0027","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1053\/jlts.2003.50224","article-title":"Role of adult living donor liver transplantation in patients with hepatitis C","volume":"9","author":"Everson","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0028|tri12642-cit-0028","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/lt.20660","article-title":"Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients","volume":"12","author":"Guo","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0029|tri12642-cit-0029","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1600-6143.2004.00704.x","article-title":"Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0030|tri12642-cit-0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/TP.0b013e3182259282","article-title":"Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up","volume":"92","author":"Jain","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0031|tri12642-cit-0031","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/lt.21138","article-title":"Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients","volume":"13","author":"Schmeding","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0032|tri12642-cit-0032","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/lt.21598","article-title":"The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age","volume":"14","author":"Selzner","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0033|tri12642-cit-0033","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/TP.0b013e31822a79d2","article-title":"Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts","volume":"92","author":"Hernandez-Alejandro","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0034|tri12642-cit-0034","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/lt.22258","article-title":"Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus","volume":"17","author":"Taner","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0035|tri12642-cit-0035","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/j.1600-6143.2006.01408.x","article-title":"The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C","volume":"6","author":"Foxton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0036|tri12642-cit-0036","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]","volume":"125","author":"Hui","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1111\/tri.12642-BIB0037|tri12642-cit-0037","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1002\/lt.21613","article-title":"Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction","volume":"14","author":"Sabharwal","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0038|tri12642-cit-0038","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/lt.21524","article-title":"The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0039|tri12642-cit-0039","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1600-6143.2009.02642.x","article-title":"Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C","volume":"9","author":"Veldt","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0040|tri12642-cit-0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.24390","article-title":"Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men","volume":"54","author":"Lai","year":"2011","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0041|tri12642-cit-0041","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.21990","article-title":"Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus","volume":"47","author":"Duclos-Vallee","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0042|tri12642-cit-0042","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jhep.2008.02.009","article-title":"Are HIV-infected patients candidates for liver transplantation?","volume":"48","author":"Samuel","year":"2008","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0043|tri12642-cit-0043","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/j.1600-6143.2011.03608.x","article-title":"Fibrosing cholestatic hepatitis in HIV\/HCV co-infected transplant patients-usefulness of early markers after liver transplantation","volume":"11","author":"Antonini","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0044|tri12642-cit-0044","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1034\/j.1600-6143.2002.20511.x","article-title":"Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation","volume":"2","author":"Humar","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0045|tri12642-cit-0045","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.dld.2013.04.006","article-title":"Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C","volume":"45","author":"Bitetto","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1111\/tri.12642-BIB0046|tri12642-cit-0046","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/lt.23554","article-title":"Interleukin-28B polymorphism in hepatitis C and liver transplantation","volume":"19","author":"Duarte-Rojo","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0047|tri12642-cit-0047","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/TP.0b013e3182547551","article-title":"The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables","volume":"94","author":"Duarte-Rojo","year":"2012","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0048|tri12642-cit-0048","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/lt.23733","article-title":"Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review","volume":"19","author":"Duarte-Rojo","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0049|tri12642-cit-0049","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24623","article-title":"Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response","volume":"55","author":"Asahina","year":"2012","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0050|tri12642-cit-0050","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2010.10.037","article-title":"Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection","volume":"55","author":"Lange","year":"2011","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0051|tri12642-cit-0051","doi-asserted-by":"crossref","first-page":"e91822","DOI":"10.1371\/journal.pone.0091822","article-title":"Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis","volume":"9","author":"Sato","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1111\/tri.12642-BIB0052|tri12642-cit-0052","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","author":"Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0053|tri12642-cit-0053","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510240606","article-title":"Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions","volume":"24","author":"Fukumoto","year":"1996","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0054|tri12642-cit-0054","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199603283341302","article-title":"Long-term outcome of hepatitis C infection after liver transplantation","volume":"334","author":"Gane","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12642-BIB0055|tri12642-cit-0055","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1053\/jhep.2000.19340","article-title":"Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation","volume":"32","author":"Sreekumar","year":"2000","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0056|tri12642-cit-0056","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/lt.21747","article-title":"Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation","volume":"15","author":"Shackel","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0057|tri12642-cit-0057","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0016-5085(99)70454-3","article-title":"European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group","volume":"117","author":"Feray","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0058|tri12642-cit-0058","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/0016-5085(95)90207-4","article-title":"Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation","volume":"108","author":"Feray","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0059|tri12642-cit-0059","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/00007890-199708150-00009","article-title":"Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome","volume":"64","author":"Gayowski","year":"1997","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0060|tri12642-cit-0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/lt.20583","article-title":"Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome","volume":"12","author":"Watt","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0061|tri12642-cit-0061","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1600-6143.2009.02649.x","article-title":"The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation","volume":"9","author":"Verna","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0062|tri12642-cit-0062","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2011.06.031","article-title":"Immunosuppression and HCV recurrence after liver transplantation","volume":"56","author":"Samonakis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0063|tri12642-cit-0063","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2006.01.005","article-title":"Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression","volume":"44","author":"Berenguer","year":"2006","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0064|tri12642-cit-0064","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2007.07.023","article-title":"Influence of steroids on HCV recurrence after liver transplantation: A prospective study","volume":"47","author":"Vivarelli","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0065|tri12642-cit-0065","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/lt.22417","article-title":"A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C","volume":"17","author":"Klintmalm","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0066|tri12642-cit-0066","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/ajt.12620","article-title":"REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C","volume":"14","author":"Levy","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0067|tri12642-cit-0067","doi-asserted-by":"crossref","first-page":"894215","DOI":"10.1155\/2012\/894215","article-title":"A randomized multicenter study comparing a tacrolimus-based protocol with and without steroids in HCV-positive liver allograft recipients","volume":"2012","author":"Neumann","year":"2012","journal-title":"J Transplant"},{"key":"10.1111\/tri.12642-BIB0068|tri12642-cit-0068","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/JVI.80.9.4510-4520.2006","article-title":"Diverse effects of cyclosporine on hepatitis C virus strain replication","volume":"80","author":"Ishii","year":"2006","journal-title":"J Virol"},{"key":"10.1111\/tri.12642-BIB0069|tri12642-cit-0069","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in\u00a0vitro","volume":"43","author":"Paeshuyse","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0070|tri12642-cit-0070","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0071|tri12642-cit-0071","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/lt.21363","article-title":"Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence","volume":"14","author":"Watashi","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0072|tri12642-cit-0072","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1600-6143.2011.03508.x","article-title":"Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS\/OPTN database","volume":"11","author":"Irish","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0073|tri12642-cit-0073","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1111\/j.1432-2277.2011.01288.x","article-title":"Does MMF really slow down fibrosis of HCV recurrence in liver transplant recipients?","volume":"24","author":"Germani","year":"2011","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12642-BIB0074|tri12642-cit-0074","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/lt.24051","article-title":"Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment","volume":"21","author":"Ruiz","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0075|tri12642-cit-0075","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0076|tri12642-cit-0076","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1053\/jlts.2003.50048","article-title":"Should HCV-related cirrhosis be a contraindication for retransplantation?","volume":"9","author":"Biggins","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0077|tri12642-cit-0077","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cld.2008.03.010","article-title":"Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted","volume":"12","author":"Verna","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1111\/tri.12642-BIB0078|tri12642-cit-0078","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.transproceed.2011.01.141","article-title":"Risk factors in liver retransplantation: a single-center experience","volume":"43","author":"Crivellin","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12642-BIB0079|tri12642-cit-0079","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.hep.2003.09.010","article-title":"Results of retransplantation for recurrent hepatitis C","volume":"38","author":"Roayaie","year":"2003","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0080|tri12642-cit-0080","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1600-6143.2007.02082.x","article-title":"Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection","volume":"8","author":"Ghabril","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0081|tri12642-cit-0081","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep.510290221","article-title":"A model to predict survival following liver retransplantation","volume":"29","author":"Rosen","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0082|tri12642-cit-0082","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.20005","article-title":"Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores","volume":"39","author":"Yao","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0083|tri12642-cit-0083","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/jlts.2003.50176","article-title":"Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome","volume":"9","author":"Yoo","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0084|tri12642-cit-0084","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0085|tri12642-cit-0085","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jhep.2010.06.006","article-title":"Retransplantation in patients with hepatitis C recurrence after liver transplantation","volume":"53","author":"Carrion","year":"2010","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0086|tri12642-cit-0086","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/jhep.2003.50328","article-title":"Validation and refinement of survival models for liver retransplantation","volume":"38","author":"Rosen","year":"2003","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0087|tri12642-cit-0087","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/TP.0b013e3181b6f20e","article-title":"Liver retransplantation of more than two grafts for recurrent failure","volume":"88","author":"Akpinar","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0088|tri12642-cit-0088","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jhep.2011.11.027","article-title":"Futility and rationing in liver retransplantation: when and how can we say no?","volume":"56","author":"Biggins","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0089|tri12642-cit-0089","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2004.06.029","article-title":"Fibrosis progression after liver transplantation in patients with recurrent hepatitis C","volume":"41","author":"Neumann","year":"2004","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0090|tri12642-cit-0090","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/gut.50.5.697","article-title":"Histology predicts cirrhotic evolution of post transplant hepatitis C","volume":"50","author":"Guido","year":"2002","journal-title":"Gut"},{"key":"10.1111\/tri.12642-BIB0091|tri12642-cit-0091","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1600-6143.2007.02107.x","article-title":"Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease","volume":"8","author":"Baiocchi","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0092|tri12642-cit-0092","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/lt.20432","article-title":"Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C","volume":"11","author":"Russo","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0093|tri12642-cit-0093","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/hep.20709","article-title":"An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1\/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis","volume":"41","author":"Lunz","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0094|tri12642-cit-0094","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/lt.20506","article-title":"Early HCV-associated stellate cell activation in aggressive recurrent HCV: what can liver allografts teach about HCV pathogenesis?","volume":"11","author":"Demetris","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0095|tri12642-cit-0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/hep.1840220209","article-title":"Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa","volume":"22","author":"Suou","year":"1995","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0096|tri12642-cit-0096","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0097|tri12642-cit-0097","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0098|tri12642-cit-0098","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/tri.12027","article-title":"Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers","volume":"26","author":"Ponziani","year":"2013","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12642-BIB0099|tri12642-cit-0099","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2014.01.157","article-title":"Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C","volume":"46","author":"Ponziani","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1111\/tri.12642-BIB0100|tri12642-cit-0100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jhep.2006.12.017","article-title":"A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C","volume":"46","author":"Angelico","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0101|tri12642-cit-0101","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0102|tri12642-cit-0102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.dld.2005.08.009","article-title":"Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen","volume":"38","author":"Biselli","year":"2006","journal-title":"Dig Liver Dis"},{"key":"10.1111\/tri.12642-BIB0103|tri12642-cit-0103","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","article-title":"Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination","volume":"40","author":"Dumortier","year":"2004","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0104|tri12642-cit-0104","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/lt.20883","article-title":"Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation","volume":"12","author":"Fernandez","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0105|tri12642-cit-0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/lt.21312","article-title":"Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon\/ribavirin therapy","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0106|tri12642-cit-0106","first-page":"561","article-title":"Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series","volume":"53","author":"Mukherjee","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"10.1111\/tri.12642-BIB0107|tri12642-cit-0107","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1478-3231.2006.01261.x","article-title":"Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series","volume":"26","author":"Mukherjee","year":"2006","journal-title":"Liver Int"},{"key":"10.1111\/tri.12642-BIB0108|tri12642-cit-0108","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/01.TP.0000129811.93072.1C","article-title":"Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy","volume":"78","author":"Neff","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0109|tri12642-cit-0109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.tp.0000225827.18034.be","article-title":"Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin","volume":"82","author":"Neumann","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0110|tri12642-cit-0110","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1600-6143.2006.01470.x","article-title":"Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin","volume":"6","author":"Oton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0111|tri12642-cit-0111","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0112|tri12642-cit-0112","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","article-title":"Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series","volume":"77","author":"Rodriguez-Luna","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0113|tri12642-cit-0113","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1399-0012.2003.00145.x","article-title":"Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C","volume":"18","author":"Ross","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1111\/tri.12642-BIB0114|tri12642-cit-0114","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2005.03795.x","article-title":"Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy","volume":"20","author":"Toniutto","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/tri.12642-BIB0115|tri12642-cit-0115","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0116|tri12642-cit-0116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.20560","article-title":"Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0117|tri12642-cit-0117","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-6143.2004.00648.x","article-title":"Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation","volume":"5","author":"Shergill","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0118|tri12642-cit-0118","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/01.TP.0000142677.12473.E5","article-title":"Preemptive therapy for hepatitis C virus after living-donor liver transplantation","volume":"78","author":"Sugawara","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/tri.12642-BIB0119|tri12642-cit-0119","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2011.12.031","article-title":"Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy","volume":"56","author":"Berenguer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0120|tri12642-cit-0120","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0121|tri12642-cit-0121","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.dld.2009.08.001","article-title":"Practice guidelines for the treatment of hepatitis C: recommendations from an AISF\/SIMIT\/SIMAST Expert Opinion Meeting","volume":"42","author":"Italian Association for the Study of the L, Italian Society of Infectious TD, Italian Society for the Study of Sexually Transmitted D","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1111\/tri.12642-BIB0122|tri12642-cit-0122","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/j.1440-1746.2006.04516.x","article-title":"Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study","volume":"22","author":"Kornberg","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/tri.12642-BIB0123|tri12642-cit-0123","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/lt.21652","article-title":"Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact","volume":"15","author":"Walter","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0124|tri12642-cit-0124","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2010.11.012","article-title":"Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients","volume":"55","author":"Selzner","year":"2011","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0125|tri12642-cit-0125","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S1590-8658(11)60080-7","article-title":"Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group","volume":"43","author":"Martin","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1111\/tri.12642-BIB0126|tri12642-cit-0126","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience","volume":"60","author":"Coilly","year":"2014","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0127|tri12642-cit-0127","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/lt.23669","article-title":"Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation","volume":"19","author":"Pungpapong","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12642-BIB0128|tri12642-cit-0128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"Electronic address eee. EASL recommendations on treatment of Hepatitis C 2015","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0129|tri12642-cit-0129","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12642-BIB0130|tri12642-cit-0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOT.0000000000000198","article-title":"New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease","volume":"20","author":"Kwo","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1111\/tri.12642-BIB0131|tri12642-cit-0131","first-page":"667A","article-title":"Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0132|tri12642-cit-0132","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2014.07.020","article-title":"Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation","volume":"61","author":"Gambato","year":"2014","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0133|tri12642-cit-0133","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0134|tri12642-cit-0134","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0135|tri12642-cit-0135","first-page":"206A","article-title":"The use of simeprevir and sofosbuvir to treat HCV G1 in the Liver Transplant Setting: The experience in 3 US Centers","volume":"60","author":"Aqel","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0136|tri12642-cit-0136","first-page":"688A","article-title":"Safety and efficacy of simeprevir and sofosbuvir in patients with decompensated cirrhosis","volume":"60","author":"Lingala","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0137|tri12642-cit-0137","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/S0168-8278(15)30014-3","article-title":"All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience","volume":"187","author":"Reddy","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0138|tri12642-cit-0138","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/S0168-8278(15)30003-9","article-title":"Ledipasvir\/Sofosbuvir with Ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR 2 trial","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12642-BIB0139|tri12642-cit-0139","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12642-BIB0140|tri12642-cit-0140","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12642-BIB0141|tri12642-cit-0141","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0142|tri12642-cit-0142","first-page":"207A","article-title":"High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: The ANRS CO23 CUPILT study","volume":"60","author":"Leroy","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0143|tri12642-cit-0143","first-page":"201A","article-title":"Multicenter experience using sofosbuvir and simeprevir with\/without ribavirin to treat HCV Genotype 1 after liver transplantation","volume":"60","author":"Pungpapong","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0144|tri12642-cit-0144","first-page":"LB4","article-title":"Safety and efficacy of new DAA-based therapy for Hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study","volume":"60","author":"Brown","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0145|tri12642-cit-0145","first-page":"200A","article-title":"Ledipasvir\/Sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study","volume":"60","author":"Reddy","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12642-BIB0146|tri12642-cit-0146","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftri.12642","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tri.12642\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T18:41:42Z","timestamp":1641062502000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tri.12642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"URL":"https:\/\/doi.org\/10.1111\/tri.12642","archive":["Portico"],"relation":{},"ISSN":["0934-0874"],"issn-type":[{"value":"0934-0874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8,11]]}}}